Predict your next investment

HEALTHCARE | Drug Discovery

See what CB Insights has to offer


Acquired | Acquired

About RuiYi

RuiYi provides a biologics drug discovery platform focused on the discovery and development of biologic therapies targeting G protein coupled receptors (GPCRs). The company was founded by Raymond Stevens, PhD., of The Scripps Research Institute (TSRI) and TSRI alumni Fei Xu, Ph.D.In March 2012, RuiYi was acquired by Anaphore. The valuation of RuiYi was undisclosed. Other terms of the deal were not released.

RuiYi Headquarter Location


Latest RuiYi News

Argenx’s partner Bird Rock Bio demonstrates potential for gerilimzumab, a novel SIMPLE antibody™ against IL-6 to treat rheumatoid arthritis

Jan 6, 2018

Date: 16/03/2016 16 March 2016 – Breda, The Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX) today reported that its partner Bird Rock Bio (formerly RuiYi) has announced that gerilimzumab, a novel SIMPLE Antibody™ neutralizing the IL-6 cytokine, has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing. Bird Rock Bio initiated two clinical trials in healthy adult volunteers focused on the pharmacokinetics of gGerilimzumab in single and multiple ascending dose studies where the compound was administered by subcutaneous injection. A total of 50 subjects were included in both studies, which assessed the safety and tolerability of gerilimzumab compared with placebo. Gerilimzumab was well tolerated and no serious adverse events were reported. Positive results from this study support advancing the compound into trials in patients with autoimmune disorders. Bird Rock Bio plans to complete submission for a pivotal trial for rheumatoid arthritis by the first half of 2016. Tim Van Hauwermeiren, CEO at argenx commented: “The favorable outcomes of the two studies for gerilimzumab represent an exciting step forward for this exceptional antibody. Gerilimzumab was originally discovered using our SIMPLE Antibody™ platform and was further differentiated with our proprietary NHance® technology in order to prolong the circulation time and improve tissue distribution of antibodies. We are very pleased with how rapidly Bird Rock Bio has successfully progressed gerilimzumab.” Browse our news items by Category or by Year Category

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RuiYi

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RuiYi is included in 1 Expert Collection, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.